Tackling Mechanisms Of Disease Resistance At Janssen
“We see the whole market really changing over the next 10 years to reflect more and more use of mechanisms other than anti-TNFs,” Sue Dillon says.
You may also be interested in...
The pharmaceuticals business is riding high at Johnson & Johnson, posting impressive gains from new launches in immunology and cancer – in particular, the May launch of Zytiga (abiraterone acetate) in the U.S. for metastatic castration-resistant prostate cancer.
Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.